OUTPACE
LIVE

Serial Number

99007063

Owner

Outpace Bio, Inc.

Attorney

Sydney R. Jensen

Filing Date

Jan 17, 2025

Add to watchlist:

No watchlists yet
View on USPTO

OUTPACE Trademark

Serial Number: 99007063

OUTPACE is a trademark filed by Outpace Bio, Inc. on January 17, 2025. The trademark is classified under Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Outpace Bio, Inc. (3 trademarks)

700 Dexter Ave N, Ste 300
Seattle, WA 98109

Entity Type: 03

Trademark Details

Filing Date

January 17, 2025

Registration Date

Not Registered

Goods & Services

Drug discovery services; pharmaceutical drug development services; product research and development; scientific research and development services; pharmaceutical research and development; development of pharmaceutical preparations and drugs; medical and scientific research and development services, namely, identification, production and development of therapeutics, cell therapies, bioengineered cells and proteins for the treatment and prevention of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; medical and scientific research and development services, namely, identification, production and development of cell therapy solutions, namely protein design and custom cell programming; scientific, medical, biotechnology, biomedical, and pharmaceutical research, development, testing and analysis services; medical and scientific research and development services, namely, protein engineering and design services; scientific and medical services, namely, human cell programming services; scientific research, development, discovery and consulting services in the fields of cell therapy and immuno-oncology; scientific research, development, engineering and testing services in the fields of therapeutics, cell therapies, biologics, medicine, and pharmaceuticals; medical research; clinical research in the fields of therapeutics, cell therapies, biologics, medicine, and pharmaceuticals; scientific research and development, scientific laboratory services, medical and scientific research, biotechnology research and synthetic biology research, all of the foregoing relating to human beings; development of pharmaceutical preparations and drugs for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; development of pharmaceutical preparations and drugs in the field of immunotherapy; development of pharmaceutical preparations and drugs in the field of cell therapy; development of pharmaceutical preparations and drugs in the field of gene therapy; medical research laboratory services, namely, biological tissue material processing and analysis in the field of cell therapy and immuno-oncology; biotechnology scientific laboratory services; scientific and medical research laboratory services; genetic engineering services, namely, for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; genetic engineering of biological cells, cellular targets, proteins, and antibodies for others; providing a website featuring information in the scientific, medical, biotechnology, biomedical, and pharmaceutical fields for the prevention and treatment of human diseases, disorders and conditions; provision of information about scientific and medical research in the field of drug discovery, development and testing; providing a website featuring information about treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders in the field of drug discovery, development and testing; provision of information about treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders in the field of prevention and treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; providing a website featuring information about prevention and treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders in the field of the prevention and treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; provision of information about prevention and treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders in the field of cell therapy and immuno-oncology; providing a website featuring information about treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders in the field of cell therapy and immuno-oncology; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; providing a website featuring information about treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders in the field of pharmaceuticals and clinical trials; provision of scientific and medical research information in the fields of biotechnology, biomedical, and pharmaceuticals; providing information about medical research relating to the diagnostic and therapeutic properties of pharmaceutical preparations and biologic preparations for the prevention and treatment of human diseases, disorders and conditions;

Filing History

NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Nov 21, 2025 GNS3
LETTER OF SUSPENSION E-MAILED
Nov 21, 2025 GNSL
SUSPENSION LETTER WRITTEN
Nov 21, 2025 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 1, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 1, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 1, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 3, 2025 GNRN
NON-FINAL ACTION E-MAILED
Jul 3, 2025 GNRT
NON-FINAL ACTION WRITTEN
Jul 3, 2025 CNRT
ASSIGNED TO EXAMINER
Jun 27, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 17, 2025 NWOS
NEW APPLICATION ENTERED
Jan 17, 2025 NWAP